What’s the current market cap for Dr Martens stock?

Dr Martens (DOCS) has a market cap of £687m as of June 07, 2026.

What is the P/E ratio for Dr Martens stock?

The price to earnings (P/E) ratio for Dr Martens (DOCS) stock is 29.67 as of June 07, 2026.

Does Dr Martens stock pay dividends?

Yes, the Dr Martens (DOCS) stock pays dividends to shareholders. As of June 07, 2026, the dividend rate is £0.0255 and the yield is 3.58%. Dr Martens has a payout ratio of 103.36% on a trailing twelve-month basis.

When is the next Dr Martens dividend payment date?

The next Dr Martens (DOCS) dividend payment is scheduled for October 07, 2026.

What is the beta indicator for Dr Martens ?

Dr Martens (DOCS) has a beta rating of 0.25. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Dr Martens stock | £DOCS Share Price

07:00

09:10

11:15

13:25

15:30

About Dr Martens

Dr. Martens, also known as Docs or DMs, is a United Kingdom-based company renowned for its iconic range of footwear, alongside a variety of clothing and accessories. The company, headquartered in Wollaston, Northamptonshire, operates primarily in the footwear manufacturing sector. Established in 1947, Dr. Martens has grown to become a symbol of self-expression and counterculture, distributing its products worldwide under the Dr. Martens brand.

Ticker

£DOCS

Sector

Consumer Discretionary

Primary listing

LSE

Employees

2,377

Headquarters

London, United Kingdom

Website

www.drmartensplc.com

Dr Martens Metrics

BasicAdvanced

£687m

29.67

£0.02

0.25

£0.03

3.58%

What the Analysts think about Dr Martens

Analyst ratings (Buy, Hold, Sell) for Dr Martens stock.

Bulls say / Bears say

Dr Martens reported a 61% increase in annual adjusted pre-tax profit to £55.0 million for FY26 and projected 'strong profit' growth next year, attributing this to strong U.S. demand and a strategy focused on fewer discounts and higher margins.

Revenue in the Americas rose 2% on a constant currency basis in the third quarter, underscoring the resilience of the company’s full-price approach in its largest market.

Dr Martens is entering new Latin American markets such as Colombia and Uruguay, broadening its presence beyond Europe and North America.

Third-quarter sales declined 3.1% to £251 million, with direct-to-consumer revenue dropping 7%, as customers in Europe and Asia-Pacific were deterred by the return to full pricing, causing shares to fall nearly 13%.

In the second half of FY26, Dr Martens reported earnings per share of 4.23 pence, which was 12.6% below analyst expectations, and revenue was slightly under estimates, indicating potential volatility in earnings performance.

U.S. import tariffs are expected to create a high single-digit million pound headwind in FY26; only half will be offset this year, maintaining pressure on margins until a full offset in FY27.

Data summarised monthly by Lightyear AI. Last updated on 31 May 2026.

Dr Martens Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Dr Martens Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by London Stock Exchange, through Infront.

Buy £DOCS

Capital at risk

Market closed

Upcoming events

Bulls say / Bears say

Revenue in the Americas rose 2% on a constant currency basis in the third quarter, underscoring the resilience of the company’s full-price approach in its largest market.

Dr Martens is entering new Latin American markets such as Colombia and Uruguay, broadening its presence beyond Europe and North America.

U.S. import tariffs are expected to create a high single-digit million pound headwind in FY26; only half will be offset this year, maintaining pressure on margins until a full offset in FY27.

Data summarised monthly by Lightyear AI. Last updated on 31 May 2026.

About Dr Martens

Ticker

Primary listing

Employees

Dr Martens Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Dr Martens

Analyst Ratings

Bulls say / Bears say

Dr Martens Financial Performance

Income Statement

Dr Martens Earnings Performance

Earnings per share (EPS)

Buy £DOCS

Upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Dr Martens /£DOCS

About Dr Martens

Ticker

Primary listing

Employees

Dr Martens Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Dr Martens

Analyst Ratings

Bulls say / Bears say

Dr Martens Financial Performance

Income Statement

Dr Martens Earnings Performance

Earnings per share (EPS)

Buy £DOCS

Upcoming events

What’s the current market cap for Dr Martens stock?

What is the P/E ratio for Dr Martens stock?

Does Dr Martens stock pay dividends?

When is the next Dr Martens dividend payment date?

What is the beta indicator for Dr Martens ?

Bulls say / Bears say